97-39-2
97-39-2
Chemical Structure
Ditolylguanidine
Synonym(s): 1,3-Di-o-tolylguanidine; DTG
- CAS No.: 97-39-2
- Formula:C15H17N3
- Molecular Weight:239.32
IUPAC Name: 1,3-di-o-tolylguanidine
InChIKey: OPNUROKCUBTKLF-UHFFFAOYSA-N
SMILES: CC1=C(NC(NC2=CC=CC=C2C)=N)C=CC=C1
Biological Activity: Ditolylguanidine (1,3-Di-o-tolylguanidine) is an agonist of sigma receptor (σ1/σ2 receptor) with Ki values of 69 and 21 nM for σ1 and σ2 receptors, respectively. Ditolylguanidine effectively inhibits the growth of small cell lung cancer cells. Ditolylguanidine can be used for the research of lung cancer[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ditolylguanidine | 99.75% | Ditolylguanidine (1,3-Di-o-tolylguanidine) is an agonist of sigma receptor (σ1/σ2 receptor) with Ki values of 69 and 21 nM for σ1 and σ2 receptors, respectively. Ditolylguanidine effectively inhibits the growth of small cell lung cancer cells. Ditolylguanidine can be used for the research of lung cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ditolylguanidine (Standard) | 99.20% | Ditolylguanidine (Standard) is the analytical standard of Ditolylguanidine. This product is intended for research and analytical applications. Ditolylguanidine (1,3-Di-o-tolylguanidine) is an agonist of sigma receptor (σ1/σ2 receptor) with Ki values of 69 and 21 nM for σ1 and σ2 receptors, respectively. Ditolylguanidine effectively inhibits the growth of small cell lung cancer cells. Ditolylguanidine can be used for the research of lung cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Shimizu I, et al. Effects of (+)-pentazocine and 1,3-di-o-tolylguanidine (DTG), sigma (sigma) ligands, on micturition in anaesthetized rats. Br J Pharmacol. 2000 Oct;131(3):610-6.
- [2]. John CS, et al. Sigma receptors are expressed in human non-small cell lung carcinoma. Life Sci. 1995;56(26):2385-92. [Content Brief]
- [3]. Moody TW, et al. Sigma ligands inhibit the growth of small cell lung cancer cells. Life Sci. 2000 Apr 7;66(20):1979-86. [Content Brief]
- [4]. Moison D, et al. Intrastriatal administration of sigma ligands inhibits basal dopamine release in vivo. Neuropharmacology. 2003 Dec;45(7):945-53. [Content Brief]
